

Interview with LIDDS' CEO Anders Månsson published on the company's website

Uppsala 4 November 2022 - LIDDS announced today that an interview with CEO Anders Månsson has been published on the company's website.

Anders Månsson took office as CEO of LIDDS on September 1, 2022. In an interview, published today on the company's website, he summarizes his view of the company's situation and the way forward.

"I assess that LIDDS has assets that can be developed with a low risk for the biotech industry, and potentially with great value creation, but very important to achieve the latter is a substantial upgrade of the business development," said Anders Månsson. The full interview can be viewed at <https://liddspharma.com/en/about-lidds/message-from-the-ceo/>.

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com

Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS' Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and solve problems within many indication areas. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage development, and projects about to enter clinical phase. The company is listed on Nasdaq First North Growth market.

Attachments

Interview with LIDDS' CEO Anders Månsson published on the company's website